Biological
zigakibart
zigakibart is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
3
75%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting2
Not yet recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
not_yet_recruiting125%
active_not_recruiting125%
recruiting250%
Recent Activity
3 active trials
Showing 4 of 4
not_yet_recruitingphase_3
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
NCT07850752
recruitingphase_3
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319
recruitingphase_2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906
active_not_recruitingphase_3
Atrasentan in Patients With IgA Nephropathy
NCT04573478
Clinical Trials (4)
Showing 4 of 4 trials
NCT07850752Phase 3
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
NCT06858319Phase 3
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT07146906Phase 2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT04573478Phase 3
Atrasentan in Patients With IgA Nephropathy
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4